Cyren (CYRNQ) 10-Q 15 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Jul. 31, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	000-26495
Entity Registrant Name	CYREN LTD.
Entity Incorporation, State or Country Code	L3
Entity Address, Address Line One	10 Ha-Menofim St.
Entity Address, Address Line Two	5th Floor
Entity Address, City or Town	Herzliya
Entity Address, Country	IL
Entity Address, Postal Zip Code	4672561
City Area Code	011
Local Phone Number	972–9–863–6888
Title of 12(b) Security	Ordinary Shares, par value ILS 3.00 per share
Trading Symbol	CYRN
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		7,790,223
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001084577
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 8,791	$ 4,288
Trade receivables (net of allowances for credit losses of $53 and $118, respectively)	1,774	352
Deferred commissions	522	482
Prepaid expenses and other receivables	1,464	1,120
Current assets held for sale (Note 3)	11,255	1,082
Total current assets	23,806	7,324
LONG-TERM ASSETS:
Long-term deferred commissions	702	521
Long-term lease deposits and prepaid expenses	643	686
Operating lease right-of-use assets	5,531	6,207
Severance pay fund	852	921
Property and equipment, net	1,377	1,980
Intangible assets, net	2,331	3,499
Goodwill	6,518	11,598
Long-term assets held for sale (Note 3)	0	13,392
Total long-term assets	17,954	38,804
Total assets	41,760	46,128
CURRENT LIABILITIES:
Trade payables	858	1,059
Employees and payroll accruals	3,631	4,196
Accrued expenses and other liabilities ($4 and $4 attributable to related parties, respectively)	1,127	937
Operating lease liabilities	1,092	1,330
Deferred revenues	5,644	3,004
Current liabilities held for sale (Note 3)	5,225	2,180
Total current liabilities	17,577	12,706
LONG-TERM LIABILITIES:
Deferred revenues	3,084	72
Convertible Debentures ($241 and $238 attributable to related parties, respectively)	8,670	8,578
Long-term operating lease liabilities	4,644	5,749
Deferred tax liability	156	167
Accrued severance pay	945	983
Other liabilities	476	517
Long-term liabilities held for sale (Note 3)	0	3,528
Total long-term liabilities	17,975	19,594
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:
Ordinary shares nominal value ILS 3.00 par value; Authorized: 80,000,000 shares as of June 30, 2022 (Unaudited) and December 31, 2021; Issued and Outstanding: 7,787,594 and 4,532,943 shares as of June 30, 2022 (Unaudited) and December 31, 2021, respectively	6,724	3,759
Additional paid-in capital	292,933	283,577
Accumulated other comprehensive loss	(2,899)	(1,877)
Accumulated deficit	(290,550)	(271,631)
Total shareholders’ equity	6,208	13,828
Total liabilities and shareholders’ equity	$ 41,760	$ 46,128

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) $ in Thousands	Jun. 30, 2022 USD ($) shares	Jun. 30, 2022 ₪ / shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2021 ₪ / shares
Statement of Financial Position [Abstract]
Net of allowances for credit losses | $	$ 53		$ 118
Accrued expenses and other liabilities attributable to related parties | $	4		4
Convertible debentures attributable to related parties | $	$ 241		$ 238
Ordinary shares, par value (in USD per share) | ₪ / shares		₪ 3		₪ 3
Ordinary shares, authorized (in shares) | shares	80,000,000		80,000,000
Ordinary shares, issued (in shares) | shares	7,787,594		4,532,943
Ordinary shares, outstanding (in shares) | shares	7,787,594		4,532,943

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenues	$ 5,752	$ 5,704	$ 11,468	$ 12,550
Cost of revenues	3,229	3,328	6,662	6,630
Gross profit	2,523	2,376	4,806	5,920
Operating expenses:
Research and development, net	3,776	3,501	7,725	7,090
Sales and marketing	2,492	2,355	4,972	4,650
General and administrative	2,270	2,125	4,794	4,100
Total operating expenses	8,538	7,981	17,491	15,840
Operating loss	(6,015)	(5,605)	(12,685)	(9,920)
Other income (expense), net	(2)	2	(2)	(17)
Financial income (expenses), net ($5 and $148 interest expense attributable to related parties, respectively)	233	(257)	111	(423)
Loss from continuing operations before taxes on income	(5,784)	(5,860)	(12,576)	(10,360)
Tax benefit (expense)	11	(2)	11	63
Net loss from continuing operations	(5,773)	(5,862)	(12,565)	(10,297)
Income (loss) from discontinued operations	(6,663)	274	(6,354)	512
Net loss	$ (12,436)	$ (5,588)	$ (18,919)	$ (9,785)
Continuing operations, per basic share (in dollars per share)	$ (0.75)	$ (1.55)	$ (1.97)	$ (2.86)
Discontinued operations, basic (in dollars per share)	(0.86)	0.07	(1)	0.14
Basic and diluted net loss per share, basic (in dollars per share)	(1.61)	(1.48)	(2.97)	(2.72)
Continuing operations, per diluted share (in dollars per share)	(0.75)	(1.55)	(1.97)	(2.86)
Discontinued operations, diluted (in dollars per share)	(0.86)	0.06	(1)	0.12
Basic and diluted net loss per share, diluted (in dollars per share)	$ (1.61)	$ (1.49)	$ (2.97)	$ (2.74)
Weighted-average number of shares used in computing basic net loss per share for continuing operations (in shares)	7,733,475	3,774,187	6,369,209	3,599,787
Weighted-average numbers of shares used in computing diluted net loss per share in discontinued operations (in shares)	7,733,475	4,538,440	6,369,209	4,349,357

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Financial expenses, net interest expense attributable to related parties	$ 5	$ 148

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (12,436)	$ (5,588)	$ (18,919)	$ (9,785)
Other comprehensive income (loss):
Foreign currency translation adjustments	(771)	172	(1,022)	(487)
Comprehensive loss	$ (13,207)	$ (5,416)	$ (19,941)	$ (10,272)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) - USD ($) $ in Thousands		Total	Number of out standing ordinary shares	Share capital	Additional paid-in capital	Accumulated other comprehensive loss	[1]	Accumulated deficit
Balance (in shares) at Dec. 31, 2020			3,063,596
Beginning balance at Dec. 31, 2020		$ 12,037		$ 2,392	$ 258,962	$ (725)		$ (248,592)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share issuance for financing, net of costs (in shares)	[2]		600,000
Share issuance for financing, net of costs	[2]	12,588		556	12,032
Restricted share units vested (in shares)			32,100
Restricted share units vested		0		30	(30)
Placement agent warrants		0		(402)	402
Payment of interest in shares (in shares)			14,572
Payment of interest in shares		259		13	246
Share-based compensation related to employees, directors and consultants		457			457
Issuance of shares upon early conversion of a Convertible Debentures (in shares)			60,074
Issuance of shares upon early conversion of a Convertible Debentures		859		55	804
Other comprehensive loss		(659)				(659)
Net loss		(4,197)						(4,197)
Balance (in shares) at Mar. 31, 2021			3,770,342
Ending balance at Mar. 31, 2021		21,344		2,644	272,873	(1,384)		(252,789)
Balance (in shares) at Dec. 31, 2020			3,063,596
Beginning balance at Dec. 31, 2020		12,037		2,392	258,962	(725)		(248,592)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(9,785)
Balance (in shares) at Jun. 30, 2021			3,782,012
Ending balance at Jun. 30, 2021		16,618		2,654	273,553	(1,212)		(258,377)
Balance (in shares) at Mar. 31, 2021			3,770,342
Beginning balance at Mar. 31, 2021		21,344		2,644	272,873	(1,384)		(252,789)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Payment of interest in shares (in shares)			11,670
Payment of interest in shares		142		10	132
Share-based compensation related to employees, directors and consultants		548			548
Other comprehensive loss		172				172
Net loss		(5,588)						(5,588)
Balance (in shares) at Jun. 30, 2021			3,782,012
Ending balance at Jun. 30, 2021		16,618		2,654	273,553	(1,212)		(258,377)
Balance (in shares) at Dec. 31, 2021			4,532,943
Beginning balance at Dec. 31, 2021		13,828		3,759	283,577	(1,877)		(271,631)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share and warrants issuance for financing, net of costs (in shares)	[3]		760,757
Share and warrants issuance for financing, net of costs	[3]	10,942		709	10,233
Restricted share units vested (in shares)			70,322
Restricted share units vested		0		9	(9)
Exercise of pre-funded warrants (in shares)			365,059
Exercise of pre-funded warrants		0		345	(345)
Issuance of whole shares in lieu of fractional shares due to reverse stock split (in shares)			15,589
Issuance of whole shares in lieu of fractional shares due to reverse stock split		0
Payment of interest in shares (in shares)			31,667
Payment of interest in shares		259		29	230
Share-based compensation related to employees, directors and consultants		630			630
Other comprehensive loss		(251)				(251)
Net loss		(6,483)						(6,483)
Balance (in shares) at Mar. 31, 2022			5,776,337
Ending balance at Mar. 31, 2022		18,925		4,851	294,316	(2,128)		(278,114)
Balance (in shares) at Dec. 31, 2021			4,532,943
Beginning balance at Dec. 31, 2021		13,828		3,759	283,577	(1,877)		(271,631)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(18,919)
Balance (in shares) at Jun. 30, 2022			7,787,594
Ending balance at Jun. 30, 2022		6,208		6,724	292,933	(2,899)		(290,550)
Balance (in shares) at Mar. 31, 2022			5,776,337
Beginning balance at Mar. 31, 2022		18,925		4,851	294,316	(2,128)		(278,114)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Restricted share units vested (in shares)			7,998
Restricted share units vested		0
Exercise of pre-funded warrants (in shares)			2,003,259
Exercise of pre-funded warrants		2		1,873	(1,871)
Share-based compensation related to employees, directors and consultants		488			488
Other comprehensive loss		(771)				(771)
Net loss		(12,436)						(12,436)
Balance (in shares) at Jun. 30, 2022			7,787,594
Ending balance at Jun. 30, 2022		$ 6,208		$ 6,724	$ 292,933	$ (2,899)		$ (290,550)
[1] 1 Relates to foreign currency translation adjustments. 2 Net of issuance costs of $1,212 3 Net of issuance costs of $1,057

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 1,057	$ 1,212

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (18,919)	$ (9,785)
Less: Income (loss) from discontinued operations	(6,354)	512
Net loss from continuing operations	(12,565)	(10,297)
Adjustments to reconcile net loss from continuing operations to net cash used in continuing operating activities:
(Gain) loss on disposal of property and equipment	(1)	17
Loss on termination of operating leases	10	0
Depreciation	757	1,023
Share-based compensation	1,105	971
Amortization of intangible assets	1,168	1,177
Amortization of deferred commissions	454	368
Operating lease right-of-use-asset	678	815
Interest on convertible notes	0	285
Interest and amortization of debt issuance costs on convertible debentures	344	343
Deferred taxes, net	(11)	(70)
Changes in assets and liabilities:
Trade receivables	(1,424)	(483)
Prepaid expenses and other receivables	(370)	(718)
Deferred commissions	(681)	(342)
Long-term lease deposits and prepaid expenses	20	15
Trade payables	(1,315)	(832)
Employees and payroll accruals, accrued expenses and other liabilities	1,206	1,624
Deferred revenues	5,668	(543)
Accrued severance pay, net	32	2
Operating lease liabilities	(1,355)	(960)
Other long-term liabilities	(41)	(180)
Net cash used in operating activities from continuing operations	(6,321)	(7,785)
Net cash provided by operating activities from discontinued operations	643	188
Net cash used in operating activities	(5,678)	(7,597)
Cash flows from investing activities:
Proceeds from sale of property and equipment	1	4
Capitalization of technology	0	(252)
Purchase of property and equipment	(170)	(129)
Net cash used in investing activities from continuing operations	(169)	(377)
Net cash used in investing activities from discontinued operations	(5)	(3)
Net cash used in investing activities	(174)	(380)
Cash flows from financing activities:
Proceeds from issuance of ordinary shares and warrants, net of issuance costs	10,942	0
Proceeds from stock issuance, net of costs	0	12,588
Proceeds from pre-funded warrants exercised	2	0
Net cash provided by financing activities	10,944	12,588
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(37)	(21)
Increase in cash, cash equivalents and restricted cash	5,055	4,590
Cash, cash equivalents and restricted cash at the beginning of the period	4,951	9,914
Cash, cash equivalents and restricted cash at the end of the period	10,006	14,504
Supplemental disclosure of non-cash transactions:
Purchase of property and equipment by credit	(19)	(319)
Operating lease right-of-use asset exchanged for lease obligations	60	0
Issuance of shares on early conversion of Convertible Debentures	0	859
Issuance of shares for payment of interest on Convertible Notes	0	143
Net change in accrued payroll expenses related to capitalization of technology	0	(10)
Reconciliation of cash, cash equivalents and restricted cash as shown in the condensed consolidated statements of cash flow:
Cash and cash equivalents	8,791	13,379
Restricted cash included in long-term restricted lease deposits	479	490
Cash, cash equivalents and restricted cash included in assets held for sale	736	635
Total cash, cash equivalents and restricted cash	$ 10,006	$ 14,504

Organization

Organization	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION	ORGANIZATION Cyren Ltd. (henceforth “Cyren”) was incorporated under the laws of the State of Israel on February 10, 1991 and its legal form is a company limited by shares. Cyren listed its shares to the public on July 15, 1999 under the name Commtouch Software Ltd. and changed its legal name to Cyren Ltd. in January 2014. Cyren and its subsidiaries, unless otherwise indicated, will be referred to in these consolidated financial statements as the “Company.” The Company is engaged in developing and marketing cyber security solutions to identify and protect threats in email, files and from the Internet. The Company sells its cloud-based solutions worldwide, in both embedded and Software-as-a-Service (SaaS) models, to Original Equipment Manufacturers (“OEMs”), service providers and enterprises. The Company operates in one reportable segment, which constitutes its reporting unit. Over the past several years, the Company has devoted substantially most of its effort to research and product development and increasing revenues through additional investments in sales & marketing. The Company has incurred losses since inception and expects to continue to incur losses for the foreseeable future. At June 30, 2022, the Company’s cash and cash equivalents position was not sufficient to fund the Company’s planned operations for at least a year beyond the the filing date of the condensed consolidated financial statements. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through a combination of utilizing existing cash on hand, reducing operating spend, potentially divesting assets, and future issuances of equity and/or debt securities. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. The condensed consolidated financial statements for the three and six months ended June 30, 2022, do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern. On February 10, 2022, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold, in a private placement, an aggregate of 760,757 ordinary shares, pre-funded warrants to purchase up to 2,368,318 ordinary shares and ordinary warrants to purchase up to 3,129,075 ordinary shares for aggregate gross proceeds of approximately $12 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The purchase price of each ordinary share and associated ordinary warrant was $3.835 and the purchase price of each pre-funded warrant and associated ordinary warrant was $3.834. The ordinary warrants have an exercise price of $3.71, are exercisable immediately and expire on August 16, 2027. The pre-funded warrants have an exercise price of $0.001 and are exercisable immediately until exercised in full. The closing of the private placement occurred on February 14, 2022. The proceeds of the offering have been and will be used for working capital and general corporate purposes. On June 1, 2022, the Company entered into a definitive Sale and Purchase Agreement (the “SPA”) with Content Services Group GmbH to sell all the equity interests in the Company’s legacy secure email gateway business and wholly owned subsidiary, Cyren GmbH (the “Cyren GmbH Transaction”). Pursuant to the SPA, the purchase price was €10.0 million in cash, subject to customary post-closing adjustments. Refer to Note 3 - Assets Held for Sale and Discontinued Operations for additional information. On August 1, 2022, the Company completed the Cyren GmbH Transaction and received the initial €9.4 million payment (equivalent to $9.6 million as of the closing date). Under the terms of the SPA, a holdback in the amount of €0.6 million (the "Holdback Amount") is currently held in an escrow to satisfy certain claims. The Holdback Amount, less deductions for claims against the Company, if any, will be released to the Company no later than twelve months after the closing date. Subsequent to the closing date, the Company paid approximately $1.0 million in expenses associated with the Cyren GmbH Transaction. Beyond that, the Company intends to use the proceeds from the sale for working capital and general corporate purposes. On May 5, 2022, the Company formed a new German subsidiary, Cyren Germany GmbH, which has assumed a portion of Cyren GmbH's former operations as of the closing of the Cyren GmbH transaction, including a datacenter and shared services center for the Company. Cyren Germany GmbH did not have operations during the second quarter of 2022.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	SIGNIFICANT ACCOUNTING POLICIES Interim Financial Statements The accompanying consolidated balance sheet as of June 30, 2022, the consolidated statements of operations, the consolidated statements of comprehensive loss for the three and six months ended June 30, 2022, and 2021, and the consolidated statements of cash flows for the six months ended June 30, 2022, and 2021, as well as the statement of changes in shareholders’ equity for the three and six months ended June 30, 2022, are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. In management’s opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of June 30, 2022, as well as its results of operations three and six months ended June 30, 2022, and 2021 and cash flows for the six months ended months ended June 30, 2022, and 2021. The results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for other interim periods or for future years. Significant Accounting Policies The accompanying unaudited interim consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report”) filed with the Securities and Exchange Commission (the “SEC”) on March 24, 2022. Other than the change described below, there have been no changes to the significant accounting policies described in the 2021 Annual Report that have had a material impact on the unaudited interim consolidated financial statements and related notes. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the Company's consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities including goodwill impairment and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Discontinued Operations A component of an entity that is disposed of by sale or abandonment is reported as discontinued operations if the transaction represents a strategic shift that will have a major effect on an entity's operations and financial results. Assets and liabilities of the discontinued operations are aggregated and reported separately in the Condensed Consolidated Balance Sheet, including the comparative prior year period. The results of discontinued operations are aggregated and presented separately in the Condensed Consolidated Statement of Operations. The disposed component cash flows are reflected as cash flows from discontinued operations within the Company’s Condensed Consolidated Statements of Cash Flows for each period presented. The Cyren GmbH Transaction was accounted for as discontinued operations and presented in the Condensed Consolidated Balance Sheet as assets and liabilities held for sale. The results of discontinued operations presented separately in the Condensed Consolidated Statement of operation as discontinued operations. Goodwill Goodwill represents the excess of the purchase price over the estimated fair value of net assets of a business acquired in a business combination. Under ASC Topic 350, Intangibles - Goodwill and Other ("ASC 350"), goodwill is not amortized, but rather is subject to impairment test at least annually. The Company performs an annual impairment test as of December 31 of each year, or more frequently if events or changes in circumstances indicate the carrying value may not be recoverable. Goodwill is tested for impairment at the reporting unit level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the reporting unit does not pass the qualitative assessment, the Company carries out a quantitative test for impairment of goodwill by comparing the fair value of the reporting unit with the carrying amount of the reporting unit that includes goodwill. The Company may bypass the qualitative assessment and proceed directly to performing the quantitative goodwill impairment test. The Company operates in one operating segment, and this segment comprises its only reporting unit. For the year ended December 31, 2021, and 2020, no impairment losses were identified. For the three and six months ended June 30, 2022, refer to Note 3. Recently Issued and Adopted Pronouncements In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06, ASC Subtopic 470-20 Debt—Debt with Conversion and Other Options and ASC 815-40 Hedging—Contracts in Entity’s Own Equity . The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted this new guidance January 1, 2022. The adoption of ASU 2020-06 did not have a material impact on the consolidated financial statements.

Assets Held for Sale and Discon

Assets Held for Sale and Discontinued Operations	6 Months Ended
	Jun. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS	ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS The Company has recorded certain assets as held for sale in its Condensed Consolidated Balance Sheets as of June 30, 2022, and December 31, 2021. Additionally, the Company has recorded a loss on classification as held for sale in its Consolidated Condensed Statements of Operations for the three and six months ended June 30, 2022, and 2021. Refer to Note 1 - Organization for additional information. The following assets and liabilities allocated to the discontinued operation are reflected as assets and liabilities of discontinued operations in the Company’s Consolidated Balance Sheets for all periods presented. The major classes of assets and liabilities included as part of discontinued operations are as follows: June 30, December 31, (USD in thousands, except share and per share amounts) (Unaudited) Assets held for sale Cash and cash equivalents $ 617 $ 14 Trade receivables (net of allowances for credit losses of $19 and $40, respectively) 286 447 Deferred commissions 429 500 Prepaid expenses and other receivables 183 121 Long-term deferred commissions 251 412 Long-term lease deposits and prepaid expenses 120 123 Operating lease right-of-use assets 2,702 3,073 Property and equipment, net 148 203 Intangible assets, net 487 805 Goodwill 12,822 8,776 Loss on classification as held for sale (6,790) — Total assets held for sale $ 11,255 $ 14,474 Liabilities held for sale Trade payables $ 42 $ 16 Employees and payroll accruals 222 218 Accrued expenses and other liabilities 55 18 Operating lease liabilities 278 288 Deferred revenues - current 1,573 1,640 Deferred revenues - long-term 385 413 Long-term operating lease liabilities 2,521 2,875 Deferred tax liability, net 149 240 Total liabilities held for sale $ 5,225 $ 5,708 The following details the Company's results of discontinued operations. Three Months Ended Six Months Ended (Unaudited and USD in thousands, except share and per share amounts) 2022 2021 2022 2021 Revenues $ 1,414 $ 1,905 $ 2,956 $ 3,816 Cost of revenues 398 477 782 970 Gross profit 1,016 1,428 2,174 2,846 Operating expenses: Research and development, net 505 609 1,001 1,270 Sales and marketing 238 376 465 719 General and administrative 171 180 335 365 Total operating expenses 914 1,165 1,801 2,354 Operating gain 102 263 373 492 Other income (expense), net — (1) 1 — Financial expenses, net (11) (30) (12) (78) Income from discontinued operations before taxes on income 91 232 362 414 Loss on classification as held for sale (6,790) — (6,790) — Total income (loss) from discontinued operations before taxes on income (6,699) 232 (6,428) 414 Tax benefit 36 42 74 98 Net loss from discontinued operations (6,663) 274 (6,354) 512

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
LEASES	LEASES The Company accounts for leases according to ASC 842, Leases . The Company determines if an arrangement is a lease and the classification of that lease at inception. Right-of-use (“ROU”) assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. For leases with terms greater than 12 months, the Company records the ROU asset and liability at commencement date based on the present value of lease payments according to their term. The Company uses incremental borrowing rates based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expenses are recognized on a straight-line basis over the lease term. In addition, the carrying amount of the ROU and lease liabilities are remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. The Company elected the practical expedient for lease agreements with a term of twelve months or less and does not recognize ROU assets and lease liabilities in respect of those agreements. The Company also elected the practical expedient to not separate lease and non-lease components for its leases. The Company has various operating leases for office space and vehicles that expire through 2028. Below is a summary of the Company’s operating ROU assets and operating lease liabilities as of June 30, 2022: Operating lease right-of-use assets $ 5,531 Operating lease liabilities, current $ 1,092 Operating lease liabilities long-term 4,644 Total operating lease liabilities $ 5,736 Minimum lease payments for the Company’s ROU assets over the remaining lease periods as of June 30, 2022, adjusted for discontinued operations, are as follows: Year ended June 30, (USD in thousands) 2022 $ 649 2023 1,303 2024 1,145 2025 1,074 2026 1,019 Thereafter 1,155 Total undiscounted lease payments $ 6,345 Less: Interest 609 Present value of lease liabilities 5,736 Premises rent expense from continued operations was $478 and $576 for the three months ended June 30, 2022, and 2021, respectively, and $1,039 and $1,206 for the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022, the Company subleases one real estate property as lessor. Sublease receipts were $69 and $157 for the three months ended June 30, 2022 and 2021, respectively, and $192 and $329 for the six months ended June 30, 2022 and 2021, respectively. The weighted-average remaining lease terms and discount rates for all operating leases were as follows as of June 30, 2022 : Weighted-average remaining lease term (years) 5.4 Weighted-average discount rate 4.09 %

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Cyren Ltd., which was incorporated in Israel, partially financed its research and development expenditures under programs sponsored by the Israel Innovation Authority (“IIA”) for the support of certain research and development activities conducted in Israel. Since the Company's inception through 2018, the Company received $6.4 million of participation payments from the IIA in connection with specific research and development. Of this amount, $2.6 million was subject to repayment to the IIA through royalties related to product sales as of June 30, 2022, and December 31, 2021. In return for the IIA’s participation in this program, the Company is committed to pay royalties at a rate of 3% of the program’s developed product sales, up to 100% of the amount of grants received plus interest at the annual LIBOR rate. For the three and six months ended June 30, 2022, and 2021, $19 thousand and $59 thousand, respectively, were recorded as cost of revenues with respect to royalties due to the IIA. The Company is not currently involved in any legal proceedings or claims.

Shareholders_ Equity

Shareholders’ Equity	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
SHAREHOLDERS’ EQUITY	SHAREHOLDERS’ EQUITY General Ordinary shares confer upon their holders the right to receive notice to participate and vote in general shareholder meetings of the Company and to receive dividends, if declared. On February 7, 2022, the Company held a Special Meeting of Shareholders (the “Special Meeting”). At the Special Meeting, the Company’s shareholders approved (i) an amendment to the Company’s Amended and Restated Articles of Association (the “Articles of Association”) to effect a reverse share split of the Company’s ordinary shares (the “Reverse Share Split”) at a ratio of not less than one-for-four and not more than one-for-twenty, with such ratio and the implementation and timing of the Reverse Share Split to be determined by the Company’s board of directors in its sole discretion within thirty days of the Special Meeting and (ii) an increase in the authorized share capital by up to NIS 216.0 million to 240.0 million and an amendment to the Company’s Articles of Association accordingly. Following the Special Meeting, on February 7, 2022, the board of directors of the Company approved a one-for-twenty Reverse Share Split and an increase in the Company’s authorized share capital by NIS 216.0 million, and the Articles of Association of the Company were amended accordingly. The Reverse Share Split became effective on February 9, 2022. Additionally, effective at the same time, the total number of ordinary shares the Company is authorized to issue after the effect of the Reverse Share Split is 80 million, the par value per ordinary share is NIS 3.00 and the authorized share capital of the Company is NIS 240.0 million. Upon the effectiveness of the Reverse Share Split, every twenty ordinary shares were automatically combined and converted into one ordinary share. Appropriate adjustments were also made to all outstanding derivative securities of the Company, including all outstanding equity awards and warrants. No fractional shares were issued in connection with the Reverse Share Split. Instead, all fractional shares (including shares underlying outstanding equity awards and warrants) were rounded up to the nearest whole ordinary share. All the ordinary shares and per share data have been retroactively adjusted for the impact of the Reverse Share Split. Issuance of Convertible Notes On December 5, 2018, the Company issued $10.0 million aggregate principal amount of convertible notes in a private offering. The notes were unsecured, unsubordinated obligations of Cyren and carried a 5.75% interest rate, payable semi-annually in (i) 50% cash and (ii) 50% cash or ordinary shares at Cyren’s election. The notes had a 3- year term and matured in December 2021. The notes were issued with a conversion price of $3.90 per share which was subject to adjustment using a weighted-average ratchet mechanism based on the size and price of future equity offerings and the total shares outstanding. On November 7, 2019, Cyren announced the closing of a rights offering that raised gross proceeds of $8.0 million. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.73. On February 16, 2021, Cyren announced securities purchase agreements with several institutional investors for the purchase and sale, in a registered direct offering, of 12.0 million of the Company’s ordinary shares at a purchase price of $1.15 per share for net proceeds of $12.6 million. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.38. On September 17, 2021, the Company issued to several institutional investors in a private placement 14,152,779 ordinary shares at a purchase price of $0.72 per share and warrants to purchase up to 14,152,779 ordinary shares at an exercise price of $0.60 per share. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.02 per share. In addition, the notes were subject to immediate conversion upon any change in control in the Company (or subject to repayment if the price in the change in control transaction is less than the conversion price). The principal balance of $10.0 million on the convertible notes was repaid upon maturity on December 5, 2021. No further obligations remain with respect to the convertible notes. The Company incurred no interest expense for the three and six months ended June 30, 2022. The Company incurred interest expense of $0.1 million and $0.3 million for the three and six months ended June 30, 2021. The Company has no accrued interest as of June 30, 2022, and December 31, 2021, respectively. Issuance of Convertible Debentures In March 2020, the Company entered into purchase agreements with a select group of accredited investors for the purchase of $10.3 million aggregate principal amount of Convertible Debentures in a private placement. Upon the closing, the Company received approximately $9.4 million (net of $0.8 million in issuance expenses). The debentures are unsecured, subordinated obligations of Cyren and carry a 5.75% interest rate per annum, payable semi-annually in cash or ordinary shares at Cyren’s election. The debentures have a four-year term and mature in March 2024, unless converted in accordance with their terms prior to maturity. The debentures have a conversion price of $15.00 per share and are convertible into 67 ordinary shares per $1.0 million principal amount of debentures. The conversion price is subject to adjustment based on the price and timing of future equity offerings and other customary adjustments. Upon the satisfaction of price and other conditions, Cyren has the right to force the conversion of the debentures. In March 2021, the Company paid semi-annual interest payments totaling, $0.3 million, which was paid through the issuance of 14,572 shares of common stock. In March 2022, the Company paid semi-annual interest payments totaling, $0.3 million, which was paid through the issuance of 31,667 shares of common stock. For the quarter ended March 31, 2021, two debenture holders converted a combined $1 million of principal plus interest of their debentures, which was a portion of their holding. The principal and interest were paid through the issuance of 60,074 shares. There were no conversions for the quarter ended June 30, 2022. The Company incurred interest expense of $170 thousand and $344 thousand for the three and six months ended June 30, 2022, of which $44 thousand and $92 thousand is related to the amortization of debt issuance costs, respectively. The Company incurred interest expense of $167 thousand and $343 thousand for the three and six months ended June 30, 2021, of which $41 thousand and $90 thousand is related to the amortization of debt issuance costs, respectively. The Company has accrued interest of $131 thousand and $137 thousand as of June 30, 2022, and December 31, 2021, respectively. The principal balance of the Convertible Debentures as of June 30, 2022, was $9.0 million. Equity Incentive Plan On December 22, 2016, the Company’s shareholders approved the 2016 Equity Incentive Plan (the “Equity Incentive Plan”). This plan, along with its Israeli appendix, replaced all then-existing employee and consultants’ stock option plans. The Equity Incentive Plan allows for the issuance of Restricted Stock Units (“RSUs”) as well as options. The options and RSUs generally vest over a period of four years. Options granted under the Equity Incentive Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon termination of the grantee’s employment or other relationship with the Company. The per share exercise price for options shall be no less than 100% of the fair market value per ordinary share on the date of grant. Any options and RSUs that are cancelled or not exercised within the option term become available for future grant. On July 30, 2019, the shareholders of the Company approved an increase in the number of ordinary shares reserved for issuance under the 2016 Equity Incentive Plan and its Israeli Appendix to a total of 560,000. As of June 30, 2022, an aggregate of 295,500 ordinary shares of the Company were available for future grant under the Equity Incentive Plan. Non-Employee Directors Stock Option Plan In 1999, the Company adopted the 1999 Directors Stock Option Plan, and in 2008, shareholders approved an extension of the term of this plan through July 13, 2019. On December 15, 2006, the plan was extended through 2016. On December 22, 2016, the Company’s shareholders approved the 2016 Non-Employee Director Equity Incentive Plan (the “Non-Employee Director Plan”). This plan, along with its Israeli appendix, replaced all existing Directors' stock option plans. The Non-Employee Director Plan allows for the issuance of RSUs as well as options. Each option and RSU granted under the Non-Employee Director Plan generally vests over a period of four years. Each option has an exercise price equal to the fair market value of the ordinary shares on the grant date of such option. Options granted under the Non-Employee Director Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon termination of the grantee's relationship with the Company. On July 30, 2019, the shareholders of the Company approved an increase in the number of ordinary shares reserved for issuance under the Non-Employee Director Plan and its Israeli Appendix to a total of 57,500 ordinary shares. As of June 30, 2022, an aggregate of 42,867 ordinary shares of the Company remains available for future grants to non-employee directors. A summary of the Company’s employees and directors’ stock option activity under the plans is as follows: (Unaudited and USD in thousands) Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2021 181,286 $ 38.58 2.74 $ — Granted — — 0 — Exercised — — 0 — Expired and forfeited (20,833) 32.60 0 — Outstanding at June 30, 2022 160,453 $ 39.65 2.47 $ — Options vested and expected to vest at June 30, 2022 157,838 $ 39.81 2.45 $ — Exercisable options at June 30, 2022 128,140 $ 41.73 2.18 $ — The aggregate intrinsic value in the tables above represents the total intrinsic value (the difference between the fair value of the Company’s ordinary shares as of the last day of each period and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on the last day of each period. No options were exercised during the quarters ended June 30, 2022, and 2021, respectively, and the intrinsic value was zero as of June 30, 2022, and 2021, respectively. The weighted-average grant date fair value of options granted to employees and directors during the quarters ended June 30, 2022, and 2021 was zero and $0.43, respectively. As of June 30, 2022, the Company had $0.4 million of unrecognized compensation expense related to non-vested stock options granted to employees and directors, expected to be recognized over a remaining weighted-average period of 1.29 years. The employee and directors’ options outstanding as of June 30, 2022, have been separated into ranges of exercise prices, as follows: Outstanding Exercisable Exercise price per share Options Weighted- Weighted- Options Weighted- $6.40 - $32.80 33,566 3.76 $ 26.09 18,125 $ 30.84 $34.00 - $40.00 33,806 1.34 $ 37.76 30,735 $ 38.10 $41.80 - $42.60 55,250 2.80 $ 41.81 42,875 $ 41.81 $46.00 - $64.00 37,831 1.86 $ 50.22 36,405 $ 50.12 Total employee and director options outstanding 160,453 2.47 $ 39.65 128,140 $ 41.73 Options to non-employees and non-directors are disclosed as follows: Issuance date Options outstanding Exercise price per share Options exercisable Exercisable through January 24, 2017 1,250 $ 40.00 1,250 Jan-23 The options vest and become exercisable at a rate of 1/16 of the options every three months. As of June 30, 2022, the Company did not have any unrecognized compensation expense related to non-employee non-vested stock options. A summary of the Company’s RSUs activity for employees, directors and non-employees under the plans is as follows: Number of Weighted- Awarded and unvested at December 31, 2021 344,307 $ 18.20 Granted 70,550 6.88 Vested (78,692) 19.66 Forfeited (72,070) 17.59 Awarded and unvested at June 30, 2022 264,095 $ 14.89 As of June 30, 2022, the Company had approximately $3.2 million of unrecognized compensation expense related to RSUs, expected to be recognized over a weighted-average period of 2.15 years. The total share-based compensation expense related to all of the Company’s equity-based awards, recognized for the three and six-month periods ended June 30, 2022 and 2021 was as follows: Three Months Ended Six Months Ended (Unaudited and USD in thousands) 2022 2021 2022 2021 Cost of revenues $ 41 $ 75 $ 109 $ 90 Research and development 54 33 103 79 Sales and marketing 100 78 186 125 General and administrative 288 342 707 677 Total share-based compensation expense from continuing operations $ 483 $ 528 $ 1,105 $ 971 Share-based compensation expense included in discontinued operations 5 20 13 34 Total share-based compensation expense $ 488 $ 548 $ 1,118 $ 1,005

Segment and Geographic Informat

Segment and Geographic Information	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
SEGMENT AND GEOGRAPHIC INFORMATION	SEGMENT AND GEOGRAPHIC INFORMATION ASC 280, Segment Reporting , establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment and derives revenues from licensing of software and sales of professional services, maintenance and technical support (see Note 1 - Organization for a brief description of the Company’s business). The following presents total revenue by solutions offered by geographic area based on the billing address of the customer: Three Months Ended Six Months Ended (Unaudited and USD in thousands) 2022 2021 2022 2021 United States $ 3,240 $ 3,142 $ 6,364 $ 7,001 Germany 462 349 847 817 Europe-Other 909 679 1,741 1,656 Asia Pacific 415 498 851 1,079 Israel 602 917 1,423 1,761 Other 124 119 242 236 Total revenue $ 5,752 $ 5,704 $ 11,468 $ 12,550 Major Customers During each of the quarters ended June 30, 2022, and 2021, 22% of the Company’s revenues were derived from its largest customer, and no other customer accounted for more than 10% of total revenue. Revenue Recognized from Beginning Deferred Revenue During the quarters ended June 30, 2022 and 2021, $3.4 million and $3.0 million of revenue was recognized from deferred revenue as of the beginning of the period, respectively. During the six months ended June 30, 2022 and 2021, $5.1 million and $6.8 million of revenue was recognized from deferred revenue as of the beginning of the period, respectively. Remaining Performance Obligations As of June 30, 2022, approximately $8.7 million of revenue is expected to be recognized from remaining performance obligations that are unsatisfied (or partially unsatisfied) for non-cancellable contracts. The Company expects to recognize revenue on approximately 43% of these remaining performance obligations during the remainder of 2022, approximately 39% in 2023, with the remainder recognized thereafter. Revenue Generated by Customer Type The following presents the Company's revenue by customer type: Three Months Ended Six Months Ended (Unaudited and USD in thousands) 2022 2021 2022 2021 OEM/Embedded Security 1 $ 5,437 $ 5,529 $ 10,874 $ 12,203 Enterprise/SMB 2 315 175 594 347 Total Revenue $ 5,752 $ 5,704 $ 11,468 $ 12,550 1 This market represents customers who embed Cyren Threat Detection Services and Threat Intelligence Feeds into their infrastructure and/or products to protect their customers and users. 2 In this market, Cyren provides enterprise and SMB customers email security products and threat intelligence to help protect their employees, data and IP. The following sets forth the Company’s long-lived tangible assets, net by geographic area: (Unaudited and USD in thousands) June 30, December 31, Israel $ 5,144 $ 5,612 United States 696 1,017 Germany 305 669 Other 763 889 Total long-lived tangible assets $ 6,908 $ 8,187

Financial Expenses, Net

Financial Expenses, Net	6 Months Ended
	Jun. 30, 2022
Financial Services Costs [Abstract]
FINANCIAL EXPENSES, NET	FINANCIAL EXPENSES, NET The following sets forth the Company’s financial income (expense), net by expense type from continuing operations: Three Months Ended Six Months Ended (Unaudited and USD in thousands) 2022 2021 2022 2021 Interest and accretion of discount $ (211) $ (309) $ (427) $ (628) Foreign currency exchange differences, net 468 48 581 207 Other (24) 4 (43) (2) Total financial expenses, net $ 233 $ (257) $ 111 $ (423)

Related Parties

Related Parties	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTIES	RELATED PARTIES The following sets forth balances with related parties: (Unaudited and USD in thousands) June 30, December 31, Interest expense accrual – Convertible Debentures 1 $ 4 $ 4 Long-term Convertible Debentures 2 241 238 1 Related to the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See Note 6 - Shareholders' Equity for further details. 2 Related to the Convertible Debentures entered into March 19, 2020. See Note 6 - Shareholders' Equity for further details. The following sets forth transactions with related parties: Three Months Ended Six Months Ended (USD in thousands) 2022 2021 2022 2021 Revenue 1 $ 25 $ — $ 50 $ — Interest expense on Convertible Notes 2 $ — $ 143 $ — $ 285 Interest expense on Convertible Debentures 3 $ 5 $ 5 $ 10 $ 10 1 Related to a new OEM customer agreement signed in Q3 2021 where the Company and this customer share an investor that qualifies as a related party for each. 2 Related to the semi-annual interest payable due in June and December related to the Convertible Note entered into December 5, 2018. The principal was repaid in December 2021. See Note 6 - Shareholders' Equity for further details. 3 Related to the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See Note 6 - Shareholders' Equity for further details.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Interim Financial Statements	Interim Financial Statements The accompanying consolidated balance sheet as of June 30, 2022, the consolidated statements of operations, the consolidated statements of comprehensive loss for the three and six months ended June 30, 2022, and 2021, and the consolidated statements of cash flows for the six months ended June 30, 2022, and 2021, as well as the statement of changes in shareholders’ equity for the three and six months ended June 30, 2022, are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. In management’s opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of June 30, 2022, as well as its results of operations three and six months ended June 30, 2022, and 2021 and cash flows for the six months ended months ended June 30, 2022, and 2021. The results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for other interim periods or for future years.
Significant Accounting Policies	Significant Accounting Policies The accompanying unaudited interim consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report”) filed with the Securities and Exchange Commission (the “SEC”) on March 24, 2022. Other than the change described below, there have been no changes to the significant accounting policies described in the 2021 Annual Report that have had a material impact on the unaudited interim consolidated financial statements and related notes.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the Company's consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities including goodwill impairment and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Discontinued Operations	Discontinued OperationsA component of an entity that is disposed of by sale or abandonment is reported as discontinued operations if the transaction represents a strategic shift that will have a major effect on an entity's operations and financial results. Assets and liabilities of the discontinued operations are aggregated and reported separately in the Condensed Consolidated Balance Sheet, including the comparative prior year period. The results of discontinued operations are aggregated and presented separately in the Condensed Consolidated Statement of Operations. The disposed component cash flows are reflected as cash flows from discontinued operations within the Company’s Condensed Consolidated Statements of Cash Flows for each period presented. The Cyren GmbH Transaction was accounted for as discontinued operations and presented in the Condensed Consolidated Balance Sheet as assets and liabilities held for sale. The results of discontinued operations presented separately in the Condensed Consolidated Statement of operation as discontinued operations.
Goodwill	Goodwill Goodwill represents the excess of the purchase price over the estimated fair value of net assets of a business acquired in a business combination. Under ASC Topic 350, Intangibles - Goodwill and Other ("ASC 350"), goodwill is not amortized, but rather is subject to impairment test at least annually. The Company performs an annual impairment test as of December 31 of each year, or more frequently if events or changes in circumstances indicate the carrying value may not be recoverable. Goodwill is tested for impairment at the reporting unit level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the reporting unit does not pass the qualitative assessment, the Company carries out a quantitative test for impairment of goodwill by comparing the fair value of the reporting unit with the carrying amount of the reporting unit that includes goodwill. The Company may bypass the qualitative assessment and proceed directly to performing the quantitative goodwill impairment test. The Company operates in one operating segment, and this segment comprises its only reporting unit.
Recently Issued and Adopted Pronouncements	Recently Issued and Adopted Pronouncements In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06, ASC Subtopic 470-20 Debt—Debt with Conversion and Other Options and ASC 815-40 Hedging—Contracts in Entity’s Own Equity . The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted this new guidance January 1, 2022. The adoption of ASU 2020-06 did not have a material impact on the consolidated financial statements.

Assets Held for Sale and Disc_2

Assets Held for Sale and Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations	The following assets and liabilities allocated to the discontinued operation are reflected as assets and liabilities of discontinued operations in the Company’s Consolidated Balance Sheets for all periods presented. The major classes of assets and liabilities included as part of discontinued operations are as follows: June 30, December 31, (USD in thousands, except share and per share amounts) (Unaudited) Assets held for sale Cash and cash equivalents $ 617 $ 14 Trade receivables (net of allowances for credit losses of $19 and $40, respectively) 286 447 Deferred commissions 429 500 Prepaid expenses and other receivables 183 121 Long-term deferred commissions 251 412 Long-term lease deposits and prepaid expenses 120 123 Operating lease right-of-use assets 2,702 3,073 Property and equipment, net 148 203 Intangible assets, net 487 805 Goodwill 12,822 8,776 Loss on classification as held for sale (6,790) — Total assets held for sale $ 11,255 $ 14,474 Liabilities held for sale Trade payables $ 42 $ 16 Employees and payroll accruals 222 218 Accrued expenses and other liabilities 55 18 Operating lease liabilities 278 288 Deferred revenues - current 1,573 1,640 Deferred revenues - long-term 385 413 Long-term operating lease liabilities 2,521 2,875 Deferred tax liability, net 149 240 Total liabilities held for sale $ 5,225 $ 5,708 The following details the Company's results of discontinued operations. Three Months Ended Six Months Ended (Unaudited and USD in thousands, except share and per share amounts) 2022 2021 2022 2021 Revenues $ 1,414 $ 1,905 $ 2,956 $ 3,816 Cost of revenues 398 477 782 970 Gross profit 1,016 1,428 2,174 2,846 Operating expenses: Research and development, net 505 609 1,001 1,270 Sales and marketing 238 376 465 719 General and administrative 171 180 335 365 Total operating expenses 914 1,165 1,801 2,354 Operating gain 102 263 373 492 Other income (expense), net — (1) 1 — Financial expenses, net (11) (30) (12) (78) Income from discontinued operations before taxes on income 91 232 362 414 Loss on classification as held for sale (6,790) — (6,790) — Total income (loss) from discontinued operations before taxes on income (6,699) 232 (6,428) 414 Tax benefit 36 42 74 98 Net loss from discontinued operations (6,663) 274 (6,354) 512

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities	Below is a summary of the Company’s operating ROU assets and operating lease liabilities as of June 30, 2022: Operating lease right-of-use assets $ 5,531 Operating lease liabilities, current $ 1,092 Operating lease liabilities long-term 4,644 Total operating lease liabilities $ 5,736
Schedule of Minimum Lease Payments	Minimum lease payments for the Company’s ROU assets over the remaining lease periods as of June 30, 2022, adjusted for discontinued operations, are as follows: Year ended June 30, (USD in thousands) 2022 $ 649 2023 1,303 2024 1,145 2025 1,074 2026 1,019 Thereafter 1,155 Total undiscounted lease payments $ 6,345 Less: Interest 609 Present value of lease liabilities 5,736
Schedule of Weighted Average Remaining Lease Terms and Discount Rates For All of Operating Leases	The weighted-average remaining lease terms and discount rates for all operating leases were as follows as of June 30, 2022 : Weighted-average remaining lease term (years) 5.4 Weighted-average discount rate 4.09 %

Shareholders_ Equity (Tables)

Shareholders’ Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Schedule of Employees and Directors' Stock Option Activity	A summary of the Company’s employees and directors’ stock option activity under the plans is as follows: (Unaudited and USD in thousands) Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2021 181,286 $ 38.58 2.74 $ — Granted — — 0 — Exercised — — 0 — Expired and forfeited (20,833) 32.60 0 — Outstanding at June 30, 2022 160,453 $ 39.65 2.47 $ — Options vested and expected to vest at June 30, 2022 157,838 $ 39.81 2.45 $ — Exercisable options at June 30, 2022 128,140 $ 41.73 2.18 $ —
Schedule of Employee and Directors’ Options Outstanding	The employee and directors’ options outstanding as of June 30, 2022, have been separated into ranges of exercise prices, as follows: Outstanding Exercisable Exercise price per share Options Weighted- Weighted- Options Weighted- $6.40 - $32.80 33,566 3.76 $ 26.09 18,125 $ 30.84 $34.00 - $40.00 33,806 1.34 $ 37.76 30,735 $ 38.10 $41.80 - $42.60 55,250 2.80 $ 41.81 42,875 $ 41.81 $46.00 - $64.00 37,831 1.86 $ 50.22 36,405 $ 50.12 Total employee and director options outstanding 160,453 2.47 $ 39.65 128,140 $ 41.73
Schedule of Options to Non-Employees and Non-Directors	Options to non-employees and non-directors are disclosed as follows: Issuance date Options outstanding Exercise price per share Options exercisable Exercisable through January 24, 2017 1,250 $ 40.00 1,250 Jan-23
Schedule of RSUs Activity for Employees, Directors and Non-Employees	A summary of the Company’s RSUs activity for employees, directors and non-employees under the plans is as follows: Number of Weighted- Awarded and unvested at December 31, 2021 344,307 $ 18.20 Granted 70,550 6.88 Vested (78,692) 19.66 Forfeited (72,070) 17.59 Awarded and unvested at June 30, 2022 264,095 $ 14.89
Schedule of Stock-Based Compensation Expense	The total share-based compensation expense related to all of the Company’s equity-based awards, recognized for the three and six-month periods ended June 30, 2022 and 2021 was as follows: Three Months Ended Six Months Ended (Unaudited and USD in thousands) 2022 2021 2022 2021 Cost of revenues $ 41 $ 75 $ 109 $ 90 Research and development 54 33 103 79 Sales and marketing 100 78 186 125 General and administrative 288 342 707 677 Total share-based compensation expense from continuing operations $ 483 $ 528 $ 1,105 $ 971 Share-based compensation expense included in discontinued operations 5 20 13 34 Total share-based compensation expense $ 488 $ 548 $ 1,118 $ 1,005

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Schedule of Total Revenue by Solutions Offered by Geographic Area	The following presents total revenue by solutions offered by geographic area based on the billing address of the customer: Three Months Ended Six Months Ended (Unaudited and USD in thousands) 2022 2021 2022 2021 United States $ 3,240 $ 3,142 $ 6,364 $ 7,001 Germany 462 349 847 817 Europe-Other 909 679 1,741 1,656 Asia Pacific 415 498 851 1,079 Israel 602 917 1,423 1,761 Other 124 119 242 236 Total revenue $ 5,752 $ 5,704 $ 11,468 $ 12,550
Schedule of Revenue Generated By Customer Type	The following presents the Company's revenue by customer type: Three Months Ended Six Months Ended (Unaudited and USD in thousands) 2022 2021 2022 2021 OEM/Embedded Security 1 $ 5,437 $ 5,529 $ 10,874 $ 12,203 Enterprise/SMB 2 315 175 594 347 Total Revenue $ 5,752 $ 5,704 $ 11,468 $ 12,550 1 This market represents customers who embed Cyren Threat Detection Services and Threat Intelligence Feeds into their infrastructure and/or products to protect their customers and users. 2 In this market, Cyren provides enterprise and SMB customers email security products and threat intelligence to help protect their employees, data and IP.
Schedule of Long-Lived Tangible Assets	The following sets forth the Company’s long-lived tangible assets, net by geographic area: (Unaudited and USD in thousands) June 30, December 31, Israel $ 5,144 $ 5,612 United States 696 1,017 Germany 305 669 Other 763 889 Total long-lived tangible assets $ 6,908 $ 8,187

Financial Expenses, Net (Tables

Financial Expenses, Net (Tables)	6 Months Ended
	Jun. 30, 2022
Financial Services Costs [Abstract]
Schedule of financial expense, net	The following sets forth the Company’s financial income (expense), net by expense type from continuing operations: Three Months Ended Six Months Ended (Unaudited and USD in thousands) 2022 2021 2022 2021 Interest and accretion of discount $ (211) $ (309) $ (427) $ (628) Foreign currency exchange differences, net 468 48 581 207 Other (24) 4 (43) (2) Total financial expenses, net $ 233 $ (257) $ 111 $ (423)

Related Parties (Tables)

Related Parties (Tables)	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Schedule of Related Party Balances	The following sets forth balances with related parties: (Unaudited and USD in thousands) June 30, December 31, Interest expense accrual – Convertible Debentures 1 $ 4 $ 4 Long-term Convertible Debentures 2 241 238 1 Related to the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See Note 6 - Shareholders' Equity for further details. 2 Related to the Convertible Debentures entered into March 19, 2020. See Note 6 - Shareholders' Equity for further details.
Schedule of Related Party Transactions	The following sets forth transactions with related parties: Three Months Ended Six Months Ended (USD in thousands) 2022 2021 2022 2021 Revenue 1 $ 25 $ — $ 50 $ — Interest expense on Convertible Notes 2 $ — $ 143 $ — $ 285 Interest expense on Convertible Debentures 3 $ 5 $ 5 $ 10 $ 10 1 Related to a new OEM customer agreement signed in Q3 2021 where the Company and this customer share an investor that qualifies as a related party for each. 2 Related to the semi-annual interest payable due in June and December related to the Convertible Note entered into December 5, 2018. The principal was repaid in December 2021. See Note 6 - Shareholders' Equity for further details. 3 Related to the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See Note 6 - Shareholders' Equity for further details.

Organization (Details)

Organization (Details) $ / shares in Units, € in Millions, $ in Millions				6 Months Ended
	Aug. 01, 2022 USD ($)	Aug. 01, 2022 EUR (€)	Feb. 10, 2022 USD ($) $ / shares shares	Jun. 30, 2022 segment	Aug. 01, 2022 EUR (€)	Jun. 01, 2022 EUR (€)	Sep. 17, 2021 $ / shares	Feb. 16, 2021 $ / shares
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of reportable segments | segment				1
Purchase price, per share (in dollars per share)							$ 0.72	$ 1.15
Exercise price, per share (in dollars per share)							$ 0.60
Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Transaction expenses | $	$ 1
Pre-Funded warrants
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Exercise price, per share (in dollars per share)			$ 0.001
Ordinary Warrants
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Exercise price, per share (in dollars per share)			$ 3.71
Private placement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of ordinary shares (in shares) | shares			760,757
Consideration received on transaction | $			$ 12
Purchase price, per share (in dollars per share)			$ 3.835
Purchase price of warrants per share (in dollars per share)			$ 3.834
Private placement | Pre-Funded warrants
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of securities called by warrants or rights (in shares) | shares			2,368,318
Private placement | Ordinary Warrants
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of securities called by warrants or rights (in shares) | shares			3,129,075
Legacy secure email gateway business and Cyren GmbH
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Payment | €						€ 10
Legacy secure email gateway business and Cyren GmbH | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Payment	$ 9.6				€ 9.4
Holdback amount | €		€ 0.6

Assets Held for Sale and Disc_3

Assets Held for Sale and Discontinued Operations - Balance Sheets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Allowance for credit losses	$ 19	$ 40
Deferred revenues - long-term	385	413
Legacy secure email gateway business and Cyren GmbH
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents	617	14
Trade receivables (net of allowances for credit losses of $19 and $40, respectively)	286	447
Deferred commissions	429	500
Prepaid expenses and other receivables	183	121
Long-term deferred commissions	251	412
Long-term lease deposits and prepaid expenses	120	123
Operating lease right-of-use assets	2,702	3,073
Property and equipment, net	148	203
Intangible assets, net	487	805
Goodwill	12,822	8,776
Loss on classification as held for sale	(6,790)	0
Total assets held for sale	11,255	14,474
Trade payables	42	16
Employees and payroll accruals	222	218
Accrued expenses and other liabilities	55	18
Operating lease liabilities	278	288
Deferred revenues - current	1,573	1,640
Long-term operating lease liabilities	2,521	2,875
Deferred tax liability, net	149	240
Total liabilities held for sale	$ 5,225	$ 5,708

Assets Held for Sale and Disc_4

Assets Held for Sale and Discontinued Operations - Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross profit	$ 1,016	$ 1,428	$ 2,174	$ 2,846
Total operating expenses	914	1,165	1,801	2,354
Operating gain	102	263	373	492
Income from discontinued operations before taxes on income	91	232	362	414
Loss on classification as held for sale	(6,790)	0	(6,790)	0
Total income (loss) from discontinued operations before taxes on income	(6,699)	232	(6,428)	414
Income (loss) from discontinued operations	(6,663)	274	(6,354)	512
Legacy secure email gateway business and Cyren GmbH
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues	1,414	1,905	2,956	3,816
Cost of revenues	398	477	782	970
Research and development, net	505	609	1,001	1,270
Sales and marketing	238	376	465	719
General and administrative	171	180	335	365
Other income (expense), net	0	(1)	1	0
Financial expenses, net	(11)	(30)	(12)	(78)
Tax benefit	$ 36	$ 42	$ 74	$ 98

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
Rent expense	$ 478	$ 576	$ 1,039	$ 1,206
Sublease receipts	$ 69	$ 157	$ 192	$ 329

Leases (Details) - Schedule of

Leases (Details) - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease right-of-use assets	$ 5,531	$ 6,207
Operating lease liabilities, current	1,092
Operating lease liabilities long-term	4,644	$ 5,749
Total operating lease liabilities	$ 5,736

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Minimum Lease Payments $ in Thousands	Jun. 30, 2022 USD ($)
Leases [Abstract]
2022	$ 649
2023	1,303
2024	1,145
2025	1,074
2026	1,019
Thereafter	1,155
Total undiscounted lease payments	6,345
Less: Interest	609
Present value of lease liabilities	$ 5,736

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of Weighted Average Remaining Lease Terms and Discount Rates For All of Operating Leases	Jun. 30, 2022
Leases [Abstract]
Weighted-average remaining lease term (years)	5 years 4 months 24 days
Weighted-average discount rate	4.09%

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Research and development	$ 6,400		$ 6,400
Subject to repayment (in Shares)	2,600		2,600
Cost of revenues	$ 19	$ 59	$ 19	$ 59
Royalty payments based on developed product sales	3%		3%
Royalty payments based on grants received	100%		100%

Shareholders_ Equity (Details)

Shareholders’ Equity (Details) ₪ / shares in Units, $ / shares in Units, ₪ in Millions

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Feb. 09, 2022 ILS (₪) ₪ / shares shares

Feb. 07, 2022 ILS (₪)

Dec. 05, 2021 USD ($)

Feb. 16, 2021 USD ($) $ / shares shares

Nov. 07, 2019 USD ($) $ / shares

Dec. 05, 2018 USD ($) $ / shares

Dec. 22, 2016

Mar. 31, 2022 USD ($) shares

Mar. 31, 2021 USD ($) shares

Mar. 31, 2020 USD ($)

Jun. 30, 2022 USD ($) $ / shares shares

Jun. 30, 2021 USD ($) $ / shares

Mar. 31, 2021 USD ($) shares

Jun. 30, 2022 USD ($) $ / shares shares

Jun. 30, 2021 USD ($)

Dec. 31, 2021 USD ($)

Feb. 10, 2022 $ / shares

Sep. 17, 2021 $ / shares shares

Jul. 30, 2019 shares

Shareholders’ Equity (Details) [Line Items]

Share capital (in new shekels) | ₪

₪ 240

Reverse stock split ratio

0.05

Ordinary share, par value (in new shekels per share) | ₪ / shares

₪ 3

Principal amount of convertible debenture

$ 10,000,000

Interest rate

5.75%

Interest payable in cash only

50%

Interest payable in cash or stock

50%

Matured term

3 years

Conversion price, per share (in dollars per share) | $ / shares

$ 3.38

$ 3.73

$ 3.90

$ 3.02

Gross proceeds

$ 8,000,000

Direct offering (in shares) | shares

12,000,000

Purchase price, per share (in dollars per share) | $ / shares

$ 1.15

$ 0.72

Net proceeds

$ 12,600,000

Shares issued (in shares) | shares

14,152,779

Share warrants (in shares) | shares

14,152,779

Exercise price, per share (in dollars per share) | $ / shares

$ 0.60

Interest expense

$ 0

$ 100,000

$ 0

$ 300,000

Net issuance expenses

$ 800,000

Interest payments

$ 300,000

$ 300,000

Issuance of shares (in shares) | shares

31,667

14,572

Converted of principal

$ 1,000,000

Principal and interest issuance of shares (in shares) | shares

60,074

Incurred interest expense

170,000

167,000

344,000

343,000

Amortization of debt issuance costs

44,000

41,000

92,000

90,000

Accrued interest

131,000

$ 137,000

Principal balance of convertible debentures

$ 9,000,000

Fair market value percentage

100%

Intrinsic value

$ 0

$ 0

0

$ 0

Weighted average grant date value of option granted (in dollars per share) | $ / shares

$ 0

$ 0.43

Unrecognized compensation expense

$ 400,000

$ 400,000

Recognized over remaining weighted average period

1 year 3 months 14 days

Equity incentive plan

Shareholders’ Equity (Details) [Line Items]

Ordinary shares reserved for issuance (in shares) | shares

295,500

295,500

Non-employee plan

Shareholders’ Equity (Details) [Line Items]

Ordinary shares available for future grant (in shares) | shares

42,867

42,867

Minimum

Shareholders’ Equity (Details) [Line Items]

Share capital (in new shekels) | ₪

₪ 216

Maximum

Shareholders’ Equity (Details) [Line Items]

Share capital (in new shekels) | ₪

240

Israeli appendix | Non-employee plan

Shareholders’ Equity (Details) [Line Items]

Number of ordinary shares reserved for issuance (in shares) | shares

57,500

Private placement

Shareholders’ Equity (Details) [Line Items]

Reverse share split (in shares) | shares

80,000,000

Purchase price, per share (in dollars per share) | $ / shares

$ 3.835

Restricted Stock Units (RSUs)

Shareholders’ Equity (Details) [Line Items]

Vesting period

4 years

Expiration term

6 years

Unrecognized compensation expense

$ 3,200,000

$ 3,200,000

Recognized over remaining weighted average period

2 years 1 month 24 days

Options

Shareholders’ Equity (Details) [Line Items]

Vesting period

4 years

Expiration term

6 years

2016 Equity Incentive Plan | Israeli appendix

Shareholders’ Equity (Details) [Line Items]

Ordinary shares reserved for issuance (in shares) | shares

560,000

Board of directors

Shareholders’ Equity (Details) [Line Items]

Share capital (in new shekels) | ₪

₪ 216

Issuance of convertible notes

Shareholders’ Equity (Details) [Line Items]

Convertible notes

$ 10,000,000

Convertible notes payable

Shareholders’ Equity (Details) [Line Items]

Principal amount of convertible debenture

10,300,000

$ 1,000,000

$ 1,000,000

Interest rate

5.75%

Convertible debentures

Shareholders’ Equity (Details) [Line Items]

Principal amount of convertible debenture

$ 9,400,000

Conversion price, per share (in dollars per share) | $ / shares

$ 15

$ 15

Convertible shares (in shares) | shares

67

Shareholders_ Equity (Details)

Shareholders’ Equity (Details) - Schedule of Employees and Directors' Stock Option Activity - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Number of options
Number of options, outstanding ending balance (in shares)	160,453	160,453
Number of options, exercisable options (in shares)	128,140	128,140
Weighted- average exercise price
Weighted average exercise price, outstanding ending balance (in USD per share)	$ 39.65	$ 39.65
Weighted average exercise price, exercisable options (in USD per share)	$ 41.73	$ 41.73
Additional Disclosures:
Weighted average remaining contractual term (years), outstanding beginning balance		2 years 5 months 19 days
Aggregate intrinsic value, exercisable options	$ 0	$ 0		$ 0
Employees and directors' stock option
Number of options
Number of options, outstanding beginning balance (in shares)		181,286
Number of options, granted (in shares)	0
Number of options, exercised (in shares)	0
Number of options, expired and forfeited (in shares)	(20,833)
Number of options, outstanding ending balance (in shares)	160,453	160,453	181,286
Number of options, options vested and expected to vest (in shares)	157,838	157,838
Number of options, exercisable options (in shares)	128,140	128,140
Weighted- average exercise price
Weighted average exercise price, outstanding beginning balance (in USD per share)		$ 38.58
Weighted average exercise price, granted (in USD per share)	$ 0
Weighted average exercise price, exercised (in USD per share)	0
Weighted average exercise price, expired and forfeited (in USD per share)	32.60
Weighted average exercise price, outstanding ending balance (in USD per share)	39.65	39.65	$ 38.58
Weighted average exercise price, options vested and expected to vest (in USD per share)	39.81	39.81
Weighted average exercise price, exercisable options (in USD per share)	$ 41.73	$ 41.73
Additional Disclosures:
Weighted average remaining contractual term (years), outstanding beginning balance			2 years 8 months 26 days
Weighted average remaining contractual term (years), outstanding ending balance		2 years 5 months 19 days
Aggregate intrinsic value, outstanding	$ 0	$ 0	$ 0
Weighted average remaining contractual term (years), options vested and expected to vest		2 years 5 months 12 days
Aggregate intrinsic value, options vested and expected to vest	0	$ 0
Weighted average remaining contractual term (years), exercisable options		2 years 2 months 4 days
Aggregate intrinsic value, exercisable options	$ 0	$ 0

Shareholders_ Equity (Details_2

Shareholders’ Equity (Details) - Schedule of Employee and Directors’ Options Outstanding	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding (in shares) | shares	160,453
Weighted- average remaining contractual life in years	2 years 5 months 19 days
Outstanding, weighted- average exercise price per share (in dollars per share)	$ 39.65
Exercisable, options exercisable (in shares) | shares	128,140
Exercisable, weighted- average exercise price per share (in dollars per share)	$ 41.73
$6.40 - $32.80
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price per share lower limit (in dollars per share)	6.40
Exercise price per share upper limit (in dollars per share)	$ 32.80
Options outstanding (in shares) | shares	33,566
Weighted- average remaining contractual life in years	3 years 9 months 3 days
Outstanding, weighted- average exercise price per share (in dollars per share)	$ 26.09
Exercisable, options exercisable (in shares) | shares	18,125
Exercisable, weighted- average exercise price per share (in dollars per share)	$ 30.84
$34.00 - $40.00
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price per share lower limit (in dollars per share)	34
Exercise price per share upper limit (in dollars per share)	$ 40
Options outstanding (in shares) | shares	33,806
Weighted- average remaining contractual life in years	1 year 4 months 2 days
Outstanding, weighted- average exercise price per share (in dollars per share)	$ 37.76
Exercisable, options exercisable (in shares) | shares	30,735
Exercisable, weighted- average exercise price per share (in dollars per share)	$ 38.10
$41.80 - $42.60
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price per share lower limit (in dollars per share)	41.80
Exercise price per share upper limit (in dollars per share)	$ 42.60
Options outstanding (in shares) | shares	55,250
Weighted- average remaining contractual life in years	2 years 9 months 18 days
Outstanding, weighted- average exercise price per share (in dollars per share)	$ 41.81
Exercisable, options exercisable (in shares) | shares	42,875
Exercisable, weighted- average exercise price per share (in dollars per share)	$ 41.81
$46.00 - $64.00
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price per share lower limit (in dollars per share)	46
Exercise price per share upper limit (in dollars per share)	$ 64
Options outstanding (in shares) | shares	37,831
Weighted- average remaining contractual life in years	1 year 10 months 9 days
Outstanding, weighted- average exercise price per share (in dollars per share)	$ 50.22
Exercisable, options exercisable (in shares) | shares	36,405
Exercisable, weighted- average exercise price per share (in dollars per share)	$ 50.12

Shareholders_ Equity (Details_3

Shareholders’ Equity (Details) - Schedule of Options to Non-Employees and Non-Directors	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Shareholders’ Equity (Details) - Schedule of options to non-employees and non-directors [Line Items]
Options outstanding (in shares)	160,453
Exercise price per share (in dollars per share) | $ / shares	$ 39.65
Options exercisable (in shares)	128,140
January 24, 2017
Shareholders’ Equity (Details) - Schedule of options to non-employees and non-directors [Line Items]
Options outstanding (in shares)	1,250
Exercise price per share (in dollars per share) | $ / shares	$ 40
Options exercisable (in shares)	1,250
Exercisable through	Jan-23

Shareholders_ Equity (Details_4

Shareholders’ Equity (Details) - Schedule of RSUs Activity for Employees, Directors and Non-Employees - Restricted Stock Units (RSUs)	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Number of RSUs
Number of RSUs awarded and unvested, beginning balance (in shares) | shares	344,307
Number of RSUs, granted (in shares) | shares	70,550
Number of RSUs, vested (in shares) | shares	(78,692)
Number of RSUs, forfeited (in shares) | shares	(72,070)
Number of RSUs awarded and unvested, ending balance (in shares) | shares	264,095
Weighted- Average Grant Date Fair Value
Weighted average grant date fair value awarded and unvested, beginning balance (in USD per share) | $ / shares	$ 18.20
Weighted average grant date fair value, granted (in USD per share) | $ / shares	6.88
Weighted average grant date fair value, vested (in USD per share) | $ / shares	19.66
Weighted average grant date fair value, forfeited (in USD per share) | $ / shares	17.59
Weighted average grant date fair value awarded and unvested, ending balance (in USD per share) | $ / shares	$ 14.89

Shareholders_ Equity (Details_5

Shareholders’ Equity (Details) - Schedule of Stock-Based Compensation Expense - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	$ 488	$ 548	$ 1,118	$ 1,005
Continuing Operations
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	483	528	1,105	971
Discontinued Operations
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	5	20	13	34
Cost of revenues
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	41	75	109	90
Research and development
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	54	33	103	79
Sales and marketing
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	100	78	186	125
General and administrative
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	$ 288	$ 342	$ 707	$ 677

Segment and Geographic Inform_3

Segment and Geographic Information - Additional Information (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) segment	Jun. 30, 2021 USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment			1
Recognized from deferred revenue	$ 3.4	$ 3	$ 5.1	$ 6.8
Revenue remaining performance obligations	$ 8.7		$ 8.7
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01
Concentration Risk [Line Items]
Revenue remaining performance obligation	43%		43%
Revenue remaining performance obligation, term	6 months		6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Concentration Risk [Line Items]
Revenue remaining performance obligation	39%		39%
Revenue remaining performance obligation, term	1 year		1 year
Revenue Benchmark | Customer Concentration Risk | Largest Customer
Concentration Risk [Line Items]
Concentration risk	22%	22%

Segment and Geographic Inform_4

Segment and Geographic Information (Details) - Schedule of Total Revenue by Solutions Offered by Geographic Area - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	$ 5,752	$ 5,704	$ 11,468	$ 12,550
United States
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	3,240	3,142	6,364	7,001
Germany
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	462	349	847	817
Europe-Other
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	909	679	1,741	1,656
Asia Pacific
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	415	498	851	1,079
Israel
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	602	917	1,423	1,761
Other
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	$ 124	$ 119	$ 242	$ 236

Segment and Geographic Inform_5

Segment and Geographic Information (Details) - Schedule of Revenue Generated By Customer Type - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue from External Customer [Line Items]
Revenues from external customers	$ 5,752	$ 5,704	$ 11,468	$ 12,550
OEM/Embedded Security
Revenue from External Customer [Line Items]
Revenues from external customers	5,437	5,529	10,874	12,203
Enterprise/SMB
Revenue from External Customer [Line Items]
Revenues from external customers	$ 315	$ 175	$ 594	$ 347

Segment and Geographic Inform_6

Segment and Geographic Information (Details) - Schedule of Long-Lived Tangible Assets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Segment and Geographic Information (Details) - Schedule of long-lived tangible assets [Line Items]
Net amount of property and equipment	$ 6,908	$ 8,187
Israel
Segment and Geographic Information (Details) - Schedule of long-lived tangible assets [Line Items]
Net amount of property and equipment	5,144	5,612
United States
Segment and Geographic Information (Details) - Schedule of long-lived tangible assets [Line Items]
Net amount of property and equipment	696	1,017
Germany
Segment and Geographic Information (Details) - Schedule of long-lived tangible assets [Line Items]
Net amount of property and equipment	305	669
Other
Segment and Geographic Information (Details) - Schedule of long-lived tangible assets [Line Items]
Net amount of property and equipment	$ 763	$ 889

Financial Expenses, Net (Detail

Financial Expenses, Net (Details) - Schedule of financial expense, net - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Expenses:
Interest and accretion of discount	$ 211	$ 309	$ 427	$ 628
Foreign currency exchange differences, net	468	48	581	207
Other	24	(4)	43	2
Financial income (expenses), net ($5 and $148 interest expense attributable to related parties, respectively)	$ 233	$ (257)	$ 111	$ (423)

Related Parties (Details) - Sch

Related Parties (Details) - Schedule of Related Party Balances - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
Interest expense accrual – convertible debentures	$ 4,000	$ 4,000
Long term convertible debentures	$ 241,000	$ 238,000

Related Parties (Details) - S_2

Related Parties (Details) - Schedule of Transactions With Related Parties - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Related Party Transactions [Abstract]
Revenue	$ 25	$ 0	$ 50	$ 0
Interest expense on Convertible Notes	0	143	0	285
Interest expense on Convertible Debentures	$ 5	$ 5	$ 10	$ 10